Agencies
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Agencies | Published : June 13, 2015 1:59 PM IST
Bone Marrow Transplant
In a breakthrough research, scientists from The Scripps Research Institute (TSRI), Florida, have developed a method to treat bone loss. The new treatment option works by manipulating a protein that could result in the development of new bone-forming cells in patients suffering from bone loss. The study was published in the journal Nature Communications.
Insights into the new stem cell treatment
The therapy focused on a protein called PPARy (known as the master regulator of fat) and its impact on the fate of stem cells derived from bone marrow (mesenchymal stem cells). Since these mesenchymal stem cells can develop into several different cell types -- including fat, connective tissues, bone and cartilage -- they have a number of potentially important therapeutic applications.
The scientists knew that a partial loss of PPARy in a genetically modified mouse model led to increased bone formation. To see if they could mimic that effect using a drug candidate, the researchers designed a new compound that could repress the biological activity of PPARy. (Read: Sedentary lifestyle causes brittle bones in humans: Study)
What did the results indicate?
The results showed that when human mesenchymal stem cells were treated with the new compound, which they called SR2595, there was a statistically significant increase in osteoblast formation, a cell type known to form bone. These findings demonstrate for the first time a new therapeutic application for drugs targeting PPARy, which has been the focus of efforts to develop insulin sensitisers to treat type 2 diabetes, said Patrick Griffin, director of the Translational Research Institute at Scripps Florida. (Read: 9 ways to prevent bone density loss)
We have already demonstrated SR2595 has suitable properties for testing in mice. The next step is to perform an in-depth analysis of the drug's efficacy in animal models of bone loss, ageing, obesity and diabetes, Griffin added. In addition to identifying a potential new therapeutic for bone loss, the study may have even broader implications.
Because PPARG is so closely related to several proteins with known roles in disease, we can potentially apply these structural insights to design new compounds for a variety of therapeutic applications, said David P. Marciano, first author of the study. (Read: 7 exercises that will improve your bone health for sure!)
Source: IANS
Image Source: Shutterstock
For more articles on diseases & conditions, visit our diseases & conditions section. For daily free health tips, sign up for our newsletter.
